Skip to main content
Premium Trial:

Request an Annual Quote

NCI Renews License for Genomatix Software

NEW YORK (GenomeWeb News) - The National Cancer Institute has renewed and extended a software licensing agreement with Genomatix Software’s US subsidiary, the Munich, Germany-based company said today.
Genomatix said the agreement marks the fourth consecutive year of the license with NCI.
Genomatix opened its US subsidiary earlier this year.
“We are extremely pleased with our progress in putting the US company on its feet, and the renewal with NCI/NIH is a huge step in firmly establishing our presence here”, said Peter Grant, CEO of the US company, in a statement.
Specific terms of the agreement were not released.
The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.